AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA

AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA to develop a blood-based Alzheimer Diagnostic Assay based on its proprietary PC-PURE technology